

Impact of Tight Glycemic Control on Outcome in Critically Ill Patients

Thesis submitted for partial fulfillment of Doctorate Degree
in Critical Care Medicine

Investigator

Mahmoud Khaled Mahmoud Nour

Supervisors

Prof. Dr. Alia Hassan Abd El-Fattah, MD

*Professor of Critical Care Medicine
Critical Care Medicine Department
Cairo University*

Dr. Mohamed Ashraf, MD.


*Asst. Professor of Critical Care Medicine
Critical Care Department
Cairo University*

Dr. Ahmed Mowafi, MD.

*Lecturer of Critical Care Medicine
Critical Care Department
Cairo University*

Cairo University

2009



Abstract


Introduction: Hyperglycemia and insulin resistance are a common occurrence in critically ill patients and are associated with adverse outcome. Thus, intensive insulin therapy is advocated increasingly for hyperglycemic intensive care unit (ICU) patients to reduce morbidity and mortality. Nevertheless convincing evidence of benefit comes mainly from trials carried out on surgical ICU patients while studies of the effects of intensive insulin therapy in mixed medical & surgical ICU patients have yielded conflicting results.

Methods: This study aimed at determining the efficacy of tight glycemic control and impact on morbidity and mortality measures in mixed medical/surgical ICU patients. On admission, sixty patients were randomly assigned to receive intensive insulin therapy (IIT) (30 patients) using insulin infusion (target blood glucose= 90-149 mg/dl) or conventional glycemic control (30 patients) (target blood glucose \leq 199 mg/dL).

Results: There was no statistically significant difference between both groups in the mean age (41.6 ± 19 vs 50 ± 23.9 years, $P = 0.13$), sex ($P = 0.6$), or the presence of history of diabetes mellitus ($P = 0.25$) but there was statistically significant higher mean APACHE II in (IIT) group (15.5 vs 13.2 , $P = 0.043$). the tight glycemic control group showed a statistically higher mean daily insulin dose (53.1 vs 12.7 units, $P < 0.001$), higher mean duration of stabilization within target blood glucose range (21.8 vs 12.2 hour ($P < 0.001$) & lower mean blood glucose level (136 vs 166.6 , $P = 0.004$) compared to conventional group. There was no statistically significant difference between the two groups as regards need for vasopressor use ($P = 0.79$) or the need for renal replacement therapy ($P = 0.71$), however, the incidence of acute kidney injury was lower in the tight control group (33.3% vs 53.3%) but lacks statistical significance ($P = 0.09$). Beneficial effect significantly was found in the tight glycemic control group regarding incidence of bacteremia ($P = 0.037$), mean duration of ICU stay (6.6 vs 14.1 days, $P = 0.03$) & accelerated weaning from mechanical ventilation (MV) (2.5 vs 8.2 days, $P = 0.028$). The tight glycemic control medical subgroup showed statistically significant less duration of ICU stay (7.9 ± 3 vs 16 ± 4.9 , $P = 0.05$). As regards the study surgical subgroup, tight glycemic control was associated with statistically significant lower bacteremia rate (6.7% vs 46.7 , $P = 0.013$), accelerated weaning from MV (0.5 vs 6.6 days, $P = 0.009$) & lower mean duration of ICU stay (5.3 vs 12 days, $P = 0.023$). There was no statistical significant difference between the two group regarding frequency of hypoglycemia [tight (16.7%) vs conventional (30%), $P = 0.063$]. We found lower mortality rate in the tight glycemic control group (26.7%) compared to conventional group (40%), yet with no statistical significance ($P = 0.412$). Meanwhile on subgroup analysis, there was statistically significant lower mortality in surgical ICU patients who assigned to receive IIT compared to those who receive conventional glycemic regimen (6.7% vs 26.7% , $P = 0.045$). Also, there was significant reduction in mortality with IIT among long stayers (> 5 days) compared to conventional group (16.7 vs 33.3% , $P = 0.05$).

Conclusion: Tight glycemic control significantly reduce morbidity in mixed medical and surgical ICU patients by the prevention of newly acquired bacteremia during ICU course, acceleration of weaning from mechanical ventilation and early discharge from intensive care unit with insignificant reduction in mortality rate among the whole mixed medical / surgical ICU patients yet with significant survival beneficial in surgical ICU patients & in mixed group of patients who stayed more than 5 days in the intensive care unit.

Keywords: Tight glycemic – mixed medical/surgical –intensive insulin.



Acknowledgement

For **ALLAH** the merciful, the compassionate, I kneel to express my gratitude for all the countless gifts I have been offered, including those who gave their hands to enable me to fulfill this work.

Thanks to **Prof. Dr. Sherif Mokhtar**, our Master & the founder of our department, we always owe him much. He offered us not only facilities to complete our work but also the spirit of being eager to gain more experience and skills. Words are not sufficient to express my deep gratitude for him.

Special thanks to **Prof. Dr. Alia Abd El-Fattah**, Prof. of Critical Care Medicine, Cairo University, for her continuous help and support. I am extremely grateful for her generous advice, guidance and assistance throughout the whole work. I owe her great deal of refining & revising this work through the long time & patience she offered me.

My true appreciation is due to **Prof. Dr. Mohamed Ashraf**, Assist. Professor of Critical Care Medicine for his meticulous supervision, kind guidance, valuable instructions, generous help, sincere efforts and fruitful encouragement.

I would deeply like to thank **Dr. Ahmed Mowafy**, Lecturer of Critical Care Medicine for his help, support and his simplicity in handling matters.


I would express my deep appreciation to **Dr. Lamiaa Hamed** for her effort in performing the statistical part of this thesis.

A special thanks for my colleagues **Dr. Ahmed Hares, & Dr. Mohamed Ameen** for their great effort.

I wish to thank deeply **Mrs. Neveen Said**, Critical Care Medicine Department for her patience in performing the computer work of this thesis.

Finally I am so thankful and honored to belong to the critical care medicine department, the land of innovation and fruitful research.

Mahmoud Khaled



Contents

Introduction	1
Aim of The Work	5
Review of Literature	
<i>Chapter I: Glucose Metabolism and Homeostasis; Physiological Overview</i>	6
<i>Chapter II: Detrimental Effects of Stress Hyperglycemia</i>	46
<i>Chapter III: Intensive Insulin Therapy In Clinical Practice</i>	68
Patients & Methods	110
Results	122
Discussion	158
Summary	190
Conclusions	195
Recommendations	197
References	198
Arabic Summary	٦-١

List of Abbreviations

ACTH	:	Adrenocorticotrophic Hormone
AKI	:	Acute Kidney Injury
AMI	:	Acute Myocardial Infarction
AMP	:	Adenosine Monophosphate
ANS	:	Autonomic Nervous System
APACHE II	:	Acute Physiology And Chronic Health Evaluation II
ARR	:	Absolute Risk Reduction
ATP	:	Adenosine Triphosphate
BG	:	Blood Glucose
CABG	:	Coronary Artery Bypass Grafting
c-GMP	:	Cyclic Guanosine Monophosphate
CIPNP	:	Critical Illness Polyneuropathy
CoA	:	Coenzyme A
CRP	:	C-Reactive Protein
DM	:	Diabetes Mellitus
DNA	:	Deoxyribo Nucleic acid
DNR	:	Do Not Resuscitate
EMG	:	Electromyogram
eNOS	:	Endothelial Nitric Oxide Synthase
GCS	:	Glasgow Coma Score
GFR	:	Glomerular Filtration Rate

GH	:	Growth Hormone
GI	:	Gastro – Intestinal
GIK	:	Glucose-Insulin-Potassium
GLUT	:	Glucose Transporter
GSIS	:	Glucose – Stimulated Insulin Secretion
HDL	:	High Density Lipoprotein
HPA	:	Hypothalamic Pituitary Adrenal
HPG	:	Hypothalamic Pituitary Gonadal
HPT	:	Hypothalamic Pituitary Thyroid
I[Kappa]B	:	Inhibitor Kappa B
ICAMS	:	Intra Cellular Adhesion Molecules
ICUs	:	Intensive Care Units
IGF-I	:	Insulin Like Growth Factor-1
IIT	:	Intensive Insulin Therapy
IL	:	Interleukin
IMGU	:	Insulin Mediated Glucose Uptake
iNOS	:	Inducible Nitric Oxide Synthase
IRS	:	Insulin Receptor Substrates
IV	:	Intravenous
Kcal	:	Kilo Calories
LDL	:	Low Density Lipoprotein
MCP-1	:	Monocyte Chemoattractant Protein-1.
MMP	:	Matrix Metalloproteinase
MMP-9	:	Matrix Metalloproteinase - 9

MV	:	Mechanical Ventilation
NAD(P)	:	Nicotinamide Adenosine Diphosphate
NF	:	Nuclear Factor
NF_κB	:	Nuclear Factor Kappa B
NMDA	:	N-Methyl-D-Aspartate
nNOS	:	Neuronal Nitric Oxide Synthase
NO	:	Nitric Oxide
NOS	:	Nitric Oxide Synthase
PCI	:	Percutaneous Coronary Intervention
POC	:	Point Of Care
RCTs	:	Randomized Controlled Trials
RNA	:	Ribonucleotide Adenosine
ROS	:	Reactive Oxygen Species
RRT	:	Renal Replacement Therpay
SC	:	Subcutaneous
SGLT	:	Sodium/Glucose Co Transporter
TGC	:	Tight Glycemic Control.
TGCIIT	:	Tight Glycemic Control By Intensive Insulin Therapy
TGF	:	Transforming Growth Factor
TNF-α	:	Tumor Necrosis Factor-alpha
VCAMS	:	Vascular Cell Adhesion Molecules
VEGF	:	Vascular Endothelial Growth Factor
WBCs	:	White Blood Cells

List of Tables

Table No.	Title	Page
Table (1)	: Factors and Conditions That Increase or Decrease Insulin Secretion	38
Table (2)	: Effects of tight glycemic control in acute illness.	74
Table (3)	: APACHE II score (acute physiology and chronic health evaluation II score).	114
Table (4)	: Initial demographic & clinical data in the two study groups.	123
Table (5)	: Morbidity data in the two study groups	125
Table (6)	: Frequency of acute renal impairment & the need for mechanical ventilatory support in the two study groups.	126
Table (7)	: Duration of mechanical ventilatory (MV) support in the two study groups	129
Table (8)	: Prevalence of diabetes in the study medical patients.	131
Table (9)	: Morbidity data in the study medical patients.	132
Table (10)	: Duration of ICU stay & mechanical ventilatory assistance in the study medical patients (tight vs conventional).	134
Table (11)	: Morbidity data in the study surgical patients	136
Table (12)	: Duration of mechanical ventilatory support in the study surgical subgroups.	139
Table (13)	: Efficacy data in the two study groups	142
Table (14)	: Mean blood glucose level in the two study groups.	144

Table (15) :	Frequency of hypoglycemia in the two study groups	145
Table (16) :	Distribution of medical and surgical patients according to their mean blood glucose level.	147
Table (17) :	Prevalance of diabetes mellitus according to the mean blood glucose level groups.	148
Table (18) :	Distribution of non-survivors in relation to their mean blood glucose level.	151
Table (19) :	Mortality data in the two study groups.	152
Table (20) :	Mortality rate after 5 days in the study groups.	153
Table (21) :	Distribution of non-survivors according to subgroups analysis.	154
Table (22) :	Mortality in the study diabetic, & non diabetic patients.	155
Table (23) :	Association between hypoglycemia & mortality	156
Table (24) :	Mortality in separate medical & surgical study subgroups.	157

List of Figures

Figure No.	Title	Page
Figure (1) :	Interconversions of the three major monosaccharides—glucose, fructose, and galactose—in liver cells	7
Figure (2) :	Chemical reactions of glycogenesis and glycogenolysis, showing also interconversions between blood glucose and liver glycogen	9
Figure (3) :	Sequence of chemical reactions for glycolysis	13
Figure (4) :	Conversion of pyruvic acid to acetyl CoA	14
Figure (5) :	Chemical reactions of the citric acid cycle, showing the release of carbon dioxide and a number of hydrogen atoms during the cycle	17
Figure (6) :	<i>Effect of insulin in enhancing the concentration of glucose inside muscle cells. In the absence of insulin (control), the intracellular glucose concentration remains near zero, despite high extracellular glucose concentrations</i>	26
Figure (7) :	<i>Effect of removing the pancreas on the approximate concentrations of blood glucose, plasma free fatty acids, and acetoacetic acid</i>	31
Figure (8) :	Effect of growth hormone, insulin, and growth hormone plus insulin on growth in a depancreatized and hypophysectomized rat	35
Figure (9) :	Basic mechanism of glucose stimulation of insulin secretion by beta cells of the pancreas (GLUT: glucose transporter)	36

Figure (10):	APACHE II scoring system on ICU admission in the two study groups.	124
Figure (11):	Frequency of acute renal impairment & the need for mechanical ventilatory support in the two study groups.	126
Figure (12):	Frequency of positive blood cultures in the two study groups	127
Figure (13):	Duration of ICU stay in the two study groups.	128
Figure (14):	Duration of mechanical ventilatory support in the two study groups.	129
Figure (15):	Prevalence of DM in the study medical patients.	131
Figure (16):	Morbidity data in the study medical patients.	133
Figure (17):	ICU stay in the study medical subgroups.	135
Figure (18):	Duration of MV in the study medical subgroups.	135
Figure (19):	Frequency of positive blood cultures acquired during ICU course in the study surgical subgroups.	137
Figure (20):	Need for mechanical ventilation in the study surgical pts.	138
Figure (21):	Duration of MV support in the study surgical subgroups	139
Figure (22):	Duration of ICU stay in the study surgical subgroups.	140
Figure (23):	Mean daily insulin dose in the two study groups.	141
Figure (24):	Duration of stabilization in the desired range in the two study groups	143
Figure (25):	Time to achieve the desired blood glucose range in the two study groups	143
Figure (26):	Mean blood glucose level in the two study groups	144
Figure (27):	Frequency of hypoglycemia in the two study	145

groups

Figure (28) :	Distribution of study population according to their mean blood glucose level.	146
Figure (29) :	Distribution of medical & surgical patients according to their mean blood glucose level.	147
Figure (30) :	Incidence of acute renal impairment and need for RRT in relation to the mean blood glucose level.	149
Figure (31) :	Need for mechanical ventilatory support	150
Figure (32) :	Distribution of non-survivors according to mean blood glucose level.	151
Figure (33) :	Mortality in the two study groups.	152
Figure (34) :	Mortality after 5 days of ICU stay in the study groups.	153
Figure (35) :	Distribution of non-survivors according to subgroup analysis.	154
Figure (36) :	Mortality in the study diabetic & non diabetic patients	155
Figure (37) :	Relation in separate between Hypoglycemia & mortality	156
Figure (38) :	Mortality medical and surgical study subgroup.	157

Introduction

*H*yperglycemia in response to critical illness has long been associated with adverse outcomes. Large observational studies have recently confirmed and fine-tuned this association reporting the lowest risk of death with blood glucose levels between 5 and 7 mmol/L or between 6 and 8 mmol/L for patients with diabetes mellitus ^(1,2). This association is thought to be causal based on potential glucose toxicity & studies in patients and animals support the hypothesis of toxicity induced by excess glucose, specifically toxicity to the mitochondria that takes up glucose independent of insulin and in proportion to the circulating levels of glucose ^(3,4,5).

The first trial that had tested the hypothesis that tight glycemic control improves outcome in critically ill patients, targeted a strictly normal blood glucose level (80-110 mg/dl) compared with usual care in adult patients in surgical intensive care units (ICUs). The intervention was labeled "intensive insulin therapy" and was found to reduce morbidity and mortality ⁽⁶⁾.

A subsequent study in a medical ICU setting documented similar organ protective effects, although not as strikingly as in the

surgical ICU study and mortality was not different in the intention to treat analysis ⁽⁷⁾.

Systematic reviews and meta-analyses have also led to differing conclusions ^(8,9). Trials that examine the impact of tight glycemic control on the outcome of critically ill patients revealed also conflicting results ⁽¹⁰⁻¹⁴⁾.

In a recent meta-analysis of 26 studies, Grisdale and colleagues ⁽¹⁵⁾ concluded that intensive insulin therapy doesn't provide an overall mortality benefit, but it may decrease mortality among surgical ICU patients. The differences among the individual studies are likely important. First, the type of patients and logistics of the intensive care units differed substantially. Second, the accuracy of insulin titration and glucose monitoring differed among studies and most importantly the blood glucose targets also differed markedly ⁽¹⁵⁾.

When used in such different ways, the term "intensive insulin therapy" (IIT) may not always describe the same intervention. In some settings, such therapy may have induced large fluctuations in blood glucose possibly with undetected hypoglycemia alternating with hyperglycemia. This might have resulted in a reduced average blood glucose level; however the fluctuations in blood glucose may

be worse than constant moderate hyperglycemia ⁽¹⁵⁾.

The issue of hypoglycemia is critical, as it represents the major fear when starting intensive insulin therapy, not surprisingly the increased incidence of hypoglycemia in the intensive insulin therapy groups justified the interruption of 2 large multicenter, prospective trials of IIT, the German VISEP & the European GLUCONTROL studies due to higher incidence of hypoglycemia (< 2.2 mmol/L) in the intensive insulin therapy groups as compared to conventional groups ^(16,17).

Although the incidence of hypoglycemia was substantial in both Leuven studies, the condition of patients who experienced hypoglycemia was not worsened as compared to those who did not present any hypoglycemic episode ^(6,7).

Application and performance of Tight Glycemic Control with Intensive Insulin Therapy (TGCIIT) definitely require the use of protocols that need to be implemented, validated and explained in details to health care professionals involved in the care of critically ill patients ⁽¹⁸⁾. The various algorithms already published have been reviewed ⁽¹⁹⁾, and discussed the steps required to implement protocols for TGCIIT ⁽²⁰⁾.